Latest news

• Novartis wins key adjuvant Taf/Mek approval in Europe

  The EMA has approved Tafinlar (dabrafenib) and Mekinist (trametinib) for the adjuvant (post-surgery) treatment of stage III melanoma patients with BRAF V600 mutations, following in the footsteps of the US

• Novartis scores but Roche misses in melanoma trials

  The combination of Novartis BRAF inhibitor Tafinlar (dabrafenib) and MEK inhibitor Mekinist (trametinib) met its objective with a 53% reduction in death or disease recurrence in the COMBI-AD trial, which ... Both ipilimumab and the combination of

• Novartis gets lung cancer OK for Tafinlar/Mekinist combo

  The European Commission has cleared BRAF inhibitor Tafinlar (dabrafenib) and MEK inhibitor Mekinist (trametinib) for patients with advanced or metastatic NSCLC whose tumours bear the BRAF V600 mutation.

• J&J gets CHMP backing for broader Darzalex use

  CHMP round-up. At its meeting last week the CHMP also gave its blessing to the combination of Novartis' Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF-positive non-small cell lung

• The UK's new Cancer Drugs Fund

  Gaining the greenlight were Novartis' Zykadia (ceritinib) for lung cancer and melanoma combination Tafinlar (dabrafenib) and Mekinist (trametinib), and Servier's Lonsurf (trifluridine/tipiracil HCl) for bowel cancer.